Internal Medicine

Partner With Us

Advertisement

Conference News

thumb description

June 12, 2026

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

Conexiant

thumb description

June 10, 2026

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

Conexiant

thumb description

June 10, 2026

COPD Severity Tied to Life Expectancy

A pooled US cohort study estimated years of life lost across airflow obstruction severity, including among adults who never smoked.

Conexiant

thumb description

June 05, 2026

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

Conexiant

thumb description

June 03, 2026

How Many US Clinicians Come From Banned Countries?

Counties with at least one clinician from a banned country were more likely to be designated primary care shortage areas.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

June 01, 2026

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

Conexiant

thumb description

May 29, 2026

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

Conexiant

thumb description

May 29, 2026

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

thumb description

May 14, 2026

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Conexiant

thumb description

May 14, 2026

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Conexiant